Voyager to Present VY1706 and VY7523 Posters at CTAD 2026
Voyager Therapeutics says its VY1706 gene therapy and VY7523 anti-tau antibody for Alzheimer’s disease will be featured in poster presentations at CTAD 2026.
Voyager Therapeutics says its VY1706 gene therapy and VY7523 anti-tau antibody for Alzheimer’s disease will be featured in poster presentations at CTAD 2026.